A Clinical Trial of Danhong Injection in Treating Acute Ischemic Stroke

Active, not recruiting

Phase 4 Results N/A

Eligibility Criteria

Inclusion Criteria

- Accord with the diagnostic criteria of cerebral infarction of "Guide of diagnosis and treatment of acute ischemic stroke in China" in 2010, and in the acute stage;
- Accord with the stroke and blood stasis type;
- Onset of acute ischemic stroke within 72 hours;
- NIHSS grade ≥ 4;
- Age ≥ 18;
- signed the inform consent form.

Exclusion Criteria

- Diagnosed with bleeding or other pathological brain disorders according to CT or MRI at baseline , such as vascular malformation, tumor, abscess or other common non ischemic cerebral disease (for multiple sclerosis);
- Patients with hrombolysis or endovascular treatment;
- Allergic constitution; the test drug allergy or its ingredients or elements allergy;
- With severe liver function damage(ALT and AST level more than 1.5 times higher than normal);
- With severe renal impairment (more than 1.5 times higher than normal amount of serum creatinine);
- With severe cardiac insufficiency (cardiac function rating level III above)
- Disabled patients of law (blind, deaf, dumb, mental retardation, mental disorder and physical disabilities caused by other reasons which affects the nerve function defect evaluation);
- With bleeding tendency or had serious bleeding within 3 months;
- Doubted or had alcohol and drug abuse history; Or who will lower the possibilities of enrollment or complicate the enrollment according to the investigaters' judgement;
- Menstrual period women, pregnant women and lactating women, pregnancy test positive or recent family planning;
- Who being in other clinical trials or had finished other clinical trials within 3 months.